Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	240	258	117	112	383	78
Revenue Growth (YoY)	-8.74%	120.51%	4.46%	-70.76%	391.03%	420.00%
Cost of Revenue	503	448	340	288	257	159
Gross Profit	-263	-190	-223	-176	126	-81
Selling, General & Admin	112	120	117	104	72	43
Operating Expenses	112	120	117	104	72	43
Operating Income	-375	-310	-340	-280	54	-124
Interest Expense	-8	-4	-2	-2	-	-
Interest & Investment Income	43	52	41	16	1	1
EBT Excluding Unusual Items	-340	-262	-301	-266	55	-123
Asset Writedown	-	-20	-	-	-	-
Pretax Income	-340	-282	-301	-266	55	-123
Income Tax Expense	1	1	6	1	2	-
Net Income	-341	-283	-307	-267	53	-123
Net Income to Common	-341	-283	-307	-267	53	-123
Shares Outstanding (Basic)	101	90	74	72	69	55
Shares Outstanding (Diluted)	101	90	74	72	74	55
Shares Change (YoY)	17.06%	21.76%	2.78%	-2.70%	35.04%	25.04%
EPS (Basic)	-3.39	-3.14	-4.15	-3.71	0.76	-2.24
EPS (Diluted)	-3.39	-3.14	-4.15	-3.71	0.71	-2.24
Free Cash Flow	-464	-176	-330	432	-282	108
Free Cash Flow Per Share	-4.61	-1.95	-4.46	6.00	-3.81	1.97
Gross Margin	-109.58%	-73.64%	-190.60%	-157.14%	32.90%	-103.85%
Operating Margin	-156.25%	-120.15%	-290.60%	-250.00%	14.10%	-158.97%
Profit Margin	-142.08%	-109.69%	-262.39%	-238.39%	13.84%	-157.69%
Free Cash Flow Margin	-193.33%	-68.22%	-282.05%	385.71%	-73.63%	138.46%
EBITDA	-365	-300	-332	-274	58	-121
EBITDA Margin	-152.08%	-116.28%	-283.76%	-244.64%	15.14%	-155.13%
D&A For EBITDA	10	10	8	6	4	3
EBIT	-375	-310	-340	-280	54	-124
EBIT Margin	-156.25%	-120.15%	-290.60%	-250.00%	14.10%	-158.97%
Effective Tax Rate	-	-	-	-	3.64%	-
Revenue as Reported	240	258	117	112	383	78

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q